Genentech has launched a phase 2a clinical study of RG6501 for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Lineage Cell Therapeutics.
The multicenter, open-label, single-arm study will evaluate the safety and activity of RG6501 (OpRegen), a retinal pigment epithelial cell therapy, in approximately 30 and up to 60 patients with geographic atrophy. The two primary objectives of the study are the evaluation of the proportion of patients with subretinal surgical delivery of OpRegen to target regions under the retina and the